Pharmaceutical giant Pfizer has acquired weight-loss drugmaker Metsera for $1 billion. However, while this deal may seem like a significant win for Pfizer, the real beneficiary is Novo Nordisk. The Danish company’s own obesity treatment market could be expanded by Metsera’s existing products, giving it a competitive edge in the growing obesity medication industry.
Source: https://www.barrons.com/articles/metsera-stock-price-pfizer-deal-novo-b464be0a